Group 1: Financial Performance - In Q1 2025, the company achieved revenue of ¥393,473,847.68, a year-on-year increase of 16.78% [4] - The net profit attributable to shareholders was ¥38,313,576.61, reflecting a year-on-year growth of 14.56% [4] - After deducting non-recurring gains and losses, the net profit attributable to shareholders was ¥38,606,346.69, with a year-on-year increase of 19.40% [4] Group 2: Industry Outlook - The medical industry in China is experiencing high-quality development driven by policy support and technological innovation [5] - Private hospitals are expected to alleviate pressure on public hospitals and provide diverse medical services, enhancing overall healthcare resource allocation [5] - Specialized hospitals are crucial for the advancement of medical science and improving healthcare quality [5] Group 3: Expansion Plans - The Beijing Sanbo Dongba new hospital project is on track to be completed by March 2026, which will enhance service capacity [6] - The Kunming Sanbo new hospital has completed site acceptance and is in the process of relocation [6] - The Xi'an Sanbo new hospital is undergoing various acceptance procedures and is expected to open in Q3 2025 [6] Group 4: Regulatory and Compliance Issues - The company maintains a commitment to compliance and has not identified any illegal activities involving its executives [10] - The chairman's recent detention is attributed to personal reasons and is not related to the company [10] - The company has established a governance structure to ensure stable operations during this period [10] Group 5: Market Challenges - The impact of medical insurance policies and procurement practices is expected to reduce income, but the company is working to enhance bed turnover and service volume [3] - The company is also integrating its supply chain to lower procurement costs and mitigate the effects of insurance policies on profits [3] - The competitive landscape in the medical service market is intensifying, affecting revenue growth [11]

脑机接口概念股午后持续走低，爱朋医疗（300753）跌近10%，均普智能跌超7%，荣泰健康 （603579）跌超6%，诚益通（300430）、三博脑科（301293）、翔宇医疗跟跌。 ...

Market Overview - The Shanghai Composite Index rose by 0.38% to 3355.26, while the Shenzhen Component Index increased by 1.03% to 10207.71, and the ChiNext Index surged by 1.74% to 2031.22 [1][3] - Over 3800 stocks in the market experienced gains, with 3834 stocks rising, 219 remaining flat, and 1355 declining [2][6] Sector Performance - Leading sectors included brain-computer interfaces, photovoltaic, copper cable high-speed connections, insurance, and military industry, which showed significant gains [1] - Conversely, sectors such as PEEK materials, soybeans, and steel experienced declines [1][18] Individual Stock Movements - Notable stocks included Donghua Software and NetEase Software, which hit the daily limit up, while other companies like Wanxing Technology and Youfang Technology also saw increases [1][14] - Geely Automobile's stock in Hong Kong rose by 5% as the company proposed a 13.6% premium privatization of its brand Zeekr [9] Trading Volume and Market Activity - The trading volume in the Shanghai and Shenzhen markets exceeded 500 billion [8] - The Hang Seng Technology Index increased by over 1% [7] Commodities - Spot silver rose by over 1%, while spot gold surpassed the $3400 per ounce mark, also increasing by over 1% [11][12]

Core Insights - Sanbo Brain Science has demonstrated strong resilience in its operations, achieving significant growth in both revenue and profitability for the year 2024 [1][2] Financial Performance - For the year 2024, Sanbo Brain Science reported a revenue of 1.429 billion yuan, an increase of 8.84% compared to the previous year [1] - The net profit attributable to shareholders exceeded 100 million yuan, reaching 105 million yuan, which represents a year-on-year growth of 34.24% [1] - The net profit excluding non-recurring gains and losses was 94 million yuan, showing a slight increase of 0.77% year-on-year [1] - Core business segments showed stable growth, with medical service revenue at 1.091 billion yuan (up 8.47%) and pharmaceutical revenue at 323 million yuan (up 7.97%) [1] Shareholder Returns - The company announced a profit distribution plan for 2024, proposing a cash dividend of 1.48 yuan per 10 shares (including tax), totaling 30.0425 million yuan [1] Business Expansion - Sanbo Brain Science operates eight hospitals across key regions in China, including five specialized neurology hospitals and three general hospitals [2] - The company has established a competitive edge in treating complex conditions, talent development, and research translation, supported by a team of expert academicians [2] - Recent acquisitions, including a supply chain company and a significant stake in another firm, have enhanced business synergies and expanded the company's operational footprint [3] Future Outlook - The company anticipates continued growth into 2025, with a first-quarter revenue increase of 16.78% to 393.4738 million yuan and a net profit growth of 14.56% [3] - Plans to expand hospital operations and enhance information technology infrastructure are in place to improve operational efficiency and service delivery [3]

Core Viewpoint - The investigation of the actual controller of Yong'an Pharmaceutical, Chen Yong, comes amid unusual stock price fluctuations, raising concerns about the company's governance and financial health [2][3]. Company Investigation - Yong'an Pharmaceutical announced that its actual controller and chairman, Chen Yong, is under investigation by the Hubei Province Hefeng County Supervisory Committee and has been detained [2][3]. - Chen Yong holds 21.54% of Yong'an Pharmaceutical's shares as of the end of March this year [2][3]. - The company did not disclose the specific reasons for Chen's investigation, stating that other board members are performing their duties normally and that the company's control and operations remain unaffected [3][4]. Stock Price Fluctuations - The stock price of Yong'an Pharmaceutical experienced significant volatility, with a surge of nearly 60% over seven trading days, attributed to rumors of soaring taurine prices [2][6]. - The stock reached a peak of 14.34 CNY per share before declining to 11.62 CNY per share following the company's clarification that the rumors were untrue [6][7]. Financial Performance - Yong'an Pharmaceutical's revenue has been declining for three consecutive years, with a net loss of 4.367 million CNY reported in the first quarter of this year [2][8]. - The company's revenues for 2022, 2023, and 2024 were 1.462 billion CNY, 973 million CNY, and 839 million CNY, respectively, with net profits of 140 million CNY, -12 million CNY, and 6.2 million CNY [8]. Legal Challenges - The company is also facing long-term challenges from a cross-border lawsuit regarding patent infringement related to its taurine products [9]. - A court ruling in February 2024 found that Yong'an Pharmaceutical did not infringe on the patents claimed by VITAWORKS IP, LLC, but the case is still ongoing due to an appeal [9].

Group 1 - The A-share brain-computer interface sector experienced an initial rise, with Aipeng Medical increasing by over 8% [1] - Chengyitong, Rongtai Health, and Xiangyu Medical all saw increases of over 5% [1] - Companies such as Dineike and Sanbo Neuroscience also followed the upward trend [1]

Core Insights - Brain-computer interface (BCI) technology enables direct communication between the brain and external devices, revolutionizing human-machine interaction and integrating advanced technologies such as neuroscience, AI, and new materials [2][4] - The global BCI industry is projected to reach $7.63 billion by 2029, indicating significant growth potential [4] - China and the United States are leading in BCI development, with a notable number of companies and products entering clinical stages [6][7] Industry Overview - The BCI industry is characterized by a competitive landscape with active companies in over 40 countries, primarily in the US and China, where the number of companies exceeds 100 [7] - As of early 2024, China holds 55.62% of the global patent technology in BCI, leading all countries [6] - The industry is still in its early stages, with many startups emerging and a significant increase in patent applications and funding events [55] Key Companies - **Qiangnao Technology**: Founded in 2018, it specializes in non-invasive BCI technology and has over 200 core patents, with a goal to help 1 million disabled individuals regain mobility [10][12] - **Brain Tiger Technology**: Established in 2021, it focuses on flexible invasive BCI technology and has made significant breakthroughs in core technologies [13][15] - **Brain Land Technology**: Founded in 2018, it integrates BCI technology with medical big data and AI, holding 147 patents as of April 2025 [20][21] - **Borecon**: Founded in 2021, it has developed high-performance BCI systems and has over 100 patents [24][25] - **Weiling Medical**: Established in 2019, it is focused on BCI technology and has initiated clinical research for implantable BCI systems [28] - **Roulint Technology**: Founded in 2020, it specializes in non-invasive BCI technology for consumer electronics and medical applications, holding 161 patents [33] - **Aipeng Medical**: Established in 2001, it has invested in BCI technology and developed several non-invasive BCI products [36][37] - **Kedou BCI**: Founded in 2016, it focuses on invasive BCI technology and has developed various microelectrodes and related devices [40][41] - **Sanbo Neuroscience**: Established in 2003, it has over 50 patents and is involved in clinical applications of BCI technology for neurological disorders [43] - **Chengyitong**: Founded in 2011, it has developed several non-invasive BCI prototypes and holds 303 patents, covering key areas of BCI technology [46] Technological Insights - BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with a focus on improving accuracy, feedback speed, and safety [50][52] - The majority of BCI product development is currently centered on non-invasive devices due to their higher safety and market acceptance [53] - As of 2024, there are 222 registered medical devices related to BCI in China, with 194 classified as Class II medical devices [53]

关于三博脑科医院管理集团股份有限公司 2024年度持续督导培训情况报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为三博脑 科医院管理集团股份有限公司（以下简称"三博脑科"、"公司"）首次公开发行 股票并在创业板上市的保荐机构，根据《深圳证券交易所上市公司自律监管指引 第 13 号——保荐业务》的相关规定，对三博脑科进行了 2024 年度持续督导培 训，报告如下： 中信证券股份有限公司 二、上市公司的配合情况 保荐机构本次持续督导培训的工作过程中，公司积极予以配合，保证了培训 工作的有序进行，达到了良好效果。 三、本次持续督导培训的结论 保荐机构按照《深圳证券交易所上市公司自律监管指引第 13 号——保荐业 务》的有关要求，对三博脑科进行了 2024 年度持续督导培训。 中信证券认为：通过本次培训，三博脑科董事、监事、高级管理人员等相关 人员加深了对相关法律法规的了解和认识，对上市公司规范运作、信息披露、董 监高职责履行、股东交易行为的相关要求有了更深层次的理解，有助于进一步提 升公司规范运作水平，本次培训达到了预期效果。 一、本次持续督导培训的基本情况 （一）保荐机构：中 ...

中信证券股份有限公司 关于三博脑科医院管理集团股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：三博脑科医院管理集 | | | --- | --- | | （以下简称"中信证券"或"保荐人"） 团股份有限公司 | | | 保荐代表人姓名：赵陆胤 联系电话：010-60837513 | | | 保荐代表人姓名：王栋 联系电话：010-60833110 | | | 现场检查人员姓名：赵陆胤、胡金涛 | | | 现场检查对应期间：2024 年 月 日-2024 年 月 日 1 1 12 31 | | | 现场检查时间：2025 年 4 月 16 日 | | | 一、现场检查事项 现场检查意见 | | | （一）公司治理 是 不适用 | 否 | | 现场检查手段： | | | 查阅了上市公司最新章程、三会议事规则及会议材料，取得上市公司董事、监事、 | | | 高级管理人员名单及其变化情况，取得上市公司关联方清单，查阅关于公司控股 | | | 股东、实际控制人、董事、监事、高级管理人员的信息披露文件及相关变更决策 | | | 文件，查看上市公司生产经营场所，对 ...

Group 1: Company Overview - Sanbo Brain Science has experienced a significant stock price drop, with a maximum intraday decline of over 12%, closing down 10.17% at 40.44 yuan per share, resulting in a market capitalization of 8.33 billion yuan [1] - The company reported a revenue of 1.429 billion yuan in 2024, representing a year-on-year growth of 8.84%, and a net profit attributable to shareholders of 105 million yuan, up 34.24% year-on-year [2][8] - Sanbo Brain Science's first-quarter report for 2025 showed total revenue of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.31 million yuan, up 14.56% year-on-year [8] Group 2: Leadership and Governance Issues - The chairman Zhang Yang was placed under investigation by the Inner Mongolia Supervisory Committee, raising concerns about potential bribery or collusion in crimes [2][4] - The company maintains that it has a robust governance structure and internal control mechanisms, asserting that the investigation will not significantly impact its daily operations [5][6] - There are questions regarding the jurisdiction of the investigation, as Sanbo Brain Science and its subsidiaries are not registered in Inner Mongolia, leading to speculation about the reasons behind the investigation [4][6] Group 3: Financial Performance and Challenges - Sanbo Brain Science's financial reports indicate a heavy reliance on its flagship hospital, with the Capital Medical University Sanbo Brain Hospital accounting for approximately 34.8% of total revenue and contributing 56.7% of net profit [9] - The company operates eight hospitals, but the financial performance of the majority is underwhelming, with significant losses reported from some facilities [9][10] - The market expectations for Sanbo Brain Science are high, as investors anticipate the replication of the success of its flagship hospital across its other facilities, highlighting a conflict between the fast-paced capital market and the slow-cycle nature of healthcare services [10] Group 4: Industry Context - The broader non-consumer private healthcare sector is facing scrutiny, with various listed companies reporting mixed financial results, indicating that being publicly listed does not guarantee success [13][14] - The number of registered private healthcare enterprises has been declining over the past five years, reflecting a cautious outlook on the industry [14] - Regulatory pressures, particularly from the National Medical Insurance Administration, have intensified, with several cases of fraud being prosecuted, further complicating the operational landscape for private healthcare providers [14]